Cure My Disease

Don't miss your cure!

 Log in / Sign up

Surgery for hidden lung cancer spread: a new hope for longer life?

NCT ID NCT06547710

Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial looks at whether surgically removing the primary lung tumor can help people with M1a stage lung cancer, where cancer cells are found in the chest lining during surgery. The study includes 66 adults aged 18–80 who have not had prior lung cancer treatment. Researchers will measure overall survival and quality of life to see if the surgery offers benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
surgical removal of the primary lung tumor
What this could lead to
If successful, this could show that removing the main tumor improves survival and quality of life for patients with lung cancer that has spread to the chest lining.
What could go wrong
This is an early-phase trial with only 66 participants, so results may not apply to everyone. Surgery carries risks like infection or breathing problems, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This clinical trial is a single-arm, multicenter, prospective, confirmatory phase II clinical study, which mainly evaluates the efficacy and safety of primary lesion resection for patients with M1a stage lung cancer who have occult pleural dissemination during surgery (Figure 1). Since it is unethical not to perform primary lesion resection during surgery for such patients, this study is a single-arm one. Primary lesion resection should be a resection that can completely remove the primary lesion, including lobectomy and sublobar resection.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures; 2. Aged 18-80 years (including critical values) when signing the informed consent form; 3. ECOG score 0 or 1; 4. No previous lung cancer surgery; 5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer; 6. Occult pleural metastasis found during surgery; 7. First-time treatment and no radiotherapy or chemotherapy. Exclusion Criteria: 1. The lesion cannot be completely removed surgically; 2. Cytological or histological pathology confirms other lung malignancies other than lung cancer; 3. Patients who have undergone lung cancer surgery before; 4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer metastatic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer metastatic Surgical resection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fudan University Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.